Crystalline forms of an androgen receptor modulator
AssigneesAragon Pharmaceuticals, Inc., Sloan-Kettering Institute for Cancer Research
InventorsAnna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
Life of this patent
Estimating the term…
Abstract
Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
Claims19
A crystalline Form D of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide that is characterized as exhibiting at least one of:
- (a) an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 6.3±0.1° 2-Theta, 13.9±0.1° 2-Theta, 16.4±0.1° 2-Theta, 17.0±0.1° 2-Theta, 23.7±0.1° 2-Theta, and 24.8±0.1° 2-Theta;
- or
- (b) an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 4.
Dependencies are inferred from the claim text.